News
Singapore start-up raises US$1.5m to redefine menstrual health
Blood aims to remove the shame and stigma around menstruation with an “innovative” approach
The Singapore-based start-up Blood has raised US$1.5m in funding to redefine period products and break down menstrual taboos.
Founded by husband and wife Caleb Leow and Peck Ying Tan, Blood aims to design better solutions in the menstrual health space and remove the shame and stigma around menstruation.
The company’s first product, a drug-free cramp relief patch, has led the pair to expand their business and include other types of menstrual care products, such as menstrual cups and pads, in their offerings.
Last year, Blood launched its corn-based menstrual pads, thought to be much safer for allergy-prone skin types, along with a cup pouch to help women use and sanitise their menstrual cups easier.
“There are a lot of innovations in the female space happening in the US and Europe – but really not so much over here,” Tan told Tech in Asia.
“We feel we can really be the forerunner in breaking the taboo.”
In 2022, Singapore secured its position as the leading market and hub for femtech innovations with 32 companies founded and operating in the country, a 45 per cent increase from the previous year.
Blood, founded in 2014, sells its products both online and offline in retail stores in Singapore, Malaysia, and Indonesia.
To date, the company said it had sold between seven to eight million products across these markets, with more than half of the total sales coming from offline stores.
Its series A round, led by DSG Consumer Partners with participation from returning investor AngelCentral, will help the company expand its team and retail presence and accelerate product development.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






